STAT+: Early results for Alterome’s KRAS drug for pancreas, lung and colon cancer arrive
Alterome presented preliminary Phase 1 results of its drug “selectively” targeting a range of KRAS mutations — drivers of cancers in the pancreas, lung and colon: